Results 211 to 220 of about 171,196 (309)

Multi-Targeted Neuroprotection by <i>Areca catechu</i> Against Cisplatin-Induced Neurotoxicity: Cellular, <i>Caenorhabditis elegans</i>, and Metabolomic Evidence. [PDF]

Int J Mol Sci
Kumaree KK, Cheong CSY, Verma K, Nadyani K, Mahamud N, Mahamad P, Tencomnao T, Prasansuklab A, Brimson JM.   +8 more
europepmc   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Transient paresthesia following polymyxin B loading dose in a critically ill patient: a case report. [PDF]

Ann Med Surg (Lond)
Joshi A, Bogati S, Khakurel S, Acharya S, Kunwor P.   +4 more
europepmc   +1 more source

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

British Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink, Iris R. Joosse, Maximilian Salcher‐Konrad, Melanie Walter, Elena Deligianni, Dimitra Tsioumela, Christos Kontogiorgis, Elita Poplavska, Iluta Žīgure, Christina E. Hoeve, Teresa Leonardo Alves, Ella D. van Vliet, Renato Ferreira‐da‐Silva, Ana Kodrič, Mitja Kos, Juan Erviti, Marta Gutiérrez‐Valencia, Luis Carlos Saiz, Sofia Kälvemark Sporrong, Emelie Karlsson, Christine Leopold, Marie L. De Bruin   +21 more
wiley   +1 more source

Advances in CAR-T therapy for central nervous system lymphoma. [PDF]

Front Immunol
Feng X, Yang J, Xu X, Kai W, Huang Y, Zhang S, Su L, Zhang L.   +7 more
europepmc   +1 more source

Cefepime exposure in prolonged or intermittent infusion in critically ill children

British Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika, Deborah Hirt, Emmanuelle Bille, Sihem Benaboud, Julie Toubiana, Pierre‐Louis Léger, Jérôme Rambaud, Agathe Béranger, Delphine Callot, Sylvain Renolleau, Jean‐Marc Treluyer, Mehdi Oualha, Noémie de Cacqueray   +12 more
wiley   +1 more source

Neurological complications of current and emerging CAR-T cell therapies. [PDF]

Neurotherapeutics
Hauswirth AG, Dietrich J.
europepmc   +1 more source

Ultrasmall Fe‐curcumin immunomodulators reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence

BMEMat, EarlyView.
This work discovered a novel research that ultrasmall Fe‐curcumin immunomodulators could reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. Abstract CAR‐T cell immunotherapy has achieved exciting success in hematologic malignancies, but the therapeutic efficacy is relatively limited in solid ...
Jiazhi Duan, Yuchan Xue, Miao Zhang, Zihao Zhang, Shiyu Peng, Minghao Sui, Han Ding, Yingying Nie, Yuemin Feng, Le Wang, Tianru Zhang, Mingchuan Yu, He Xia, Hong Liu, Qiang Zhu, Songbo Zhao   +15 more
wiley   +1 more source

Kolaviron offers significant neuroprotection on potassium dichromate-induced neurobehavioral, biochemical, histopathological, and immunohistochemical changes in rats. [PDF]

IBRO Neurosci Rep
Ajibade TO, Adeyemi SO, Esan OO, Olaifa OS, Adeogun AV, Adewumi SS, Uruakpa GO, Igado OO, Oyagbemi TO, Ajiboye EO, Femi-Olabisi FJ, Omobowale TO, Oguntibeju OO, Nwulia E, Yakubu MA, Jaja IF, Oyagbemi AA.   +16 more
europepmc   +1 more source